These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25395978)

  • 1. The effectiveness of cross-tapering switching to ziprasidone in patients with schizophrenia or schizoaffective disorder.
    Ko YH; Na KS; Kim CE; Kim SH; Jeon YW; Yi JS; Lee MS; Kim SG; Jeong HG; Jung HY
    Psychiatry Investig; 2014 Oct; 11(4):459-66. PubMed ID: 25395978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
    Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
    J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
    Weiden PJ; Simpson GM; Potkin SG; O'Sullivan RL
    J Clin Psychiatry; 2003 May; 64(5):580-8. PubMed ID: 12755663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to ziprasidone in the clinical practice setting: an open-label study.
    Gutiérrez Fraile M; de la Gándara Martín JJ; Bobes García J
    Int J Psychiatry Med; 2013; 45(2):125-42. PubMed ID: 23977817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: a multicenter, prospective, and naturalistic study.
    Díaz-Marsá M; Sánchez S; Rico-Villademoros F;
    J Clin Psychiatry; 2009 Apr; 70(4):509-17. PubMed ID: 19358789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial.
    Kudla D; Lambert M; Domin S; Kasper S; Naber D
    Eur Psychiatry; 2007 Apr; 22(3):195-202. PubMed ID: 17140769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone.
    Weiden PJ; Newcomer JW; Loebel AD; Yang R; Lebovitz HE
    Neuropsychopharmacology; 2008 Apr; 33(5):985-94. PubMed ID: 17637612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies.
    Keck PE; Reeves KR; Harrigan EP;
    J Clin Psychopharmacol; 2001 Feb; 21(1):27-35. PubMed ID: 11199944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
    Zhang Y; Dai G
    Hum Psychopharmacol; 2012 Nov; 27(6):605-14. PubMed ID: 24446539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
    Goff DC; Posever T; Herz L; Simmons J; Kletti N; Lapierre K; Wilner KD; Law CG; Ko GN
    J Clin Psychopharmacol; 1998 Aug; 18(4):296-304. PubMed ID: 9690695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
    Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
    Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study.
    Brook S; Walden J; Benattia I; Siu CO; Romano SJ
    Psychopharmacology (Berl); 2005 Apr; 178(4):514-23. PubMed ID: 15650846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.
    Simpson GM; Weiden P; Pigott T; Murray S; Siu CO; Romano SJ
    Am J Psychiatry; 2005 Aug; 162(8):1535-8. PubMed ID: 16055779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia.
    Lindenmayer JP; Tedeschi F; Yusim A; Khan A; Kaushik S; Smith RC; Parakadavil M
    Clin Schizophr Relat Psychoses; 2012 Jan; 5(4):185-92. PubMed ID: 22182455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of switching to ziprasidone in italian patients with acute exacerbation of schizophrenia: an open-label trial.
    Mencacci C;
    Pharmacopsychiatry; 2012 Sep; 45(6):236-40. PubMed ID: 22592506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study.
    Chen Y; Bobo WV; Watts K; Jayathilake K; Tang T; Meltzer HY
    J Psychopharmacol; 2012 Sep; 26(9):1201-10. PubMed ID: 22234928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.
    Zhao T; Park TW; Yang JC; Huang GB; Kim MG; Lee KH; Chung YC
    Int Clin Psychopharmacol; 2012 Jul; 27(4):184-90. PubMed ID: 22426471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
    Zimbroff D; Warrington L; Loebel A; Yang R; Siu C
    Int Clin Psychopharmacol; 2007 Nov; 22(6):363-70. PubMed ID: 17917555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.